Novartis AG will acquire Avidity Biosciences, Inc. for $12B, aiming to strengthen its neuroscience franchise. Learn more ...

CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients living with a severe ...

According to the agreement, Avidity ( NASDAQ: RNA) shareholders will receive $72 a share in cash, a 46% premium to Friday’s ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

An international research team, led by Shinghua Ding at the University of Missouri, has identified a previously unknown ...

Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...

His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

Now, a story about a mighty mouse, a skinny man, some Belgian cattle, and a remarkable scientific discovery. The outcome could change the lives of hundreds of thousands of people with muscle-wasting ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...

Tate was living an illness when she died at just 23, shortly after appearing in the series premiere of ‘9-1-1: Nashville.’ ...